drugset / Trial / NCT01817751

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

NCT01817751

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of the combination of three drugs, sorafenib (Nexavar®), valproic acid (Depakote®), and sildenafil (Viagra®), when used to treat high-grade glioma, a type of brain tumor.

Timeline

Start
2013-04-11
Primary completion
2020-08-27
Completion
2023-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Sildenafil Unknown 50 mg Oral
Subject Sorafenib Small molecule 400 mg Oral
Subject Valproic Acid Small molecule Oral